Clinical Trials
42 trialsA Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
GCND
Fudan University
BAYOU
AstraZeneca
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
Jonsson Comprehensive Cancer Center
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
ENHANCE
Hoosier Cancer Research Network
POSTCARD
Institut Cancerologie de l'Ouest
TRIFECTA
University of Washington
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
Canadian Cancer Trials Group
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Ohio State University Comprehensive Cancer Center
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
University of Washington
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
IMMUNOPRESERVE
Spanish Oncology Genito-Urinary Group
CALYPSO
Queen Mary University of London
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
AstraZeneca
A Study of Olaparib and Durvalumab in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
AARDVARC
AstraZeneca
WIRE
Cambridge University Hospitals NHS Foundation Trust
DUTRENEO
Fundacion CRIS de Investigación para Vencer el Cáncer
RADIANT
Ottawa Hospital Research Institute
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
H. Lee Moffitt Cancer Center and Research Institute
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
Hellenic GenitoUrinary Cancer Group
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Memorial Sloan Kettering Cancer Center
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Latin American Cooperative Oncology Group
APACHE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ARCADIA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
DOMINATION
University Health Network, Toronto
PIVOT-RCC
Washington University School of Medicine
NITIMIB
Insel Gruppe AG, University Hospital Bern
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
NEODURVARIB
Spanish Oncology Genito-Urinary Group
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Washington University School of Medicine
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
University of California, San Francisco